Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
https://pubmed.ncbi.nlm.nih.gov/38777590/
ACTRN12621000654853
A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
compared to placebo in participants with symptomatic kneE osteoarthritis
(OA) and dysLipidemia (MaRVeL Study)
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853
Name
Arthropharm Pty Ltd
https://www.arthropharm.com.au/
research reports and media, page-4100
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.5¢ | 24.5¢ | $223.2K | 903.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 91303 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 119762 | 5 |
View Market Depth
| Last trade - 13.14pm 26/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |